According to recent reports, on October 22, GUSHENGTANG (02273) established a strategic partnership with the Singapore-based integrated digital healthcare platform 1doc. The collaboration aims to systematically introduce Traditional Chinese Medicine (TCM) services into Western medicine family clinics in Singapore, providing a combined clinical diagnosis, daily healthcare, and community health experience through integrative medical practice. This partnership marks a significant milestone in the deep integration of TCM into Singapore's mainstream healthcare system and holds substantial importance for the internationalization of Traditional Chinese Medicine.
During the signing ceremony, representatives from both parties included Dr. Lan Binming, Chairman of IHG, Singapore’s former Senior Minister of Health and Transport; XU Lillian, Founder and CEO of IHG; TU Zhiliang, Founder and Chairman of GUSHENGTANG; and Lin Xiaoyan, Vice President of GUSHENGTANG, along with Vice President Zheng Xiang.
Under the framework of this cooperation, 1doc will designate independent TCM treatment areas within its existing clinic network, with GUSHENGTANG holding a 70% stake and being fully responsible for operations, while 1doc will hold a 30% stake to jointly conduct TCM business. This equity structure ensures the deep embedding and specialized operation of TCM services within Western medical settings. Through this collaborative model, patients can receive integrated medical solutions that cover the entire health management cycle, from prevention and diagnosis to rehabilitation.
In the treatment process, GUSHENGTANG practitioners will be able to issue necessary laboratory tests to enhance the objectivity and accuracy of diagnoses, using clear quantitative indicators to boost patient understanding and trust in the treatment plans, thereby improving patient compliance.
The Singaporean government has been actively promoting the integration of TCM and Western medicine. In 2025, the Ministry of Health introduced the "TCM Integration Sandbox Program," which aims to test and evaluate TCM treatment solutions in public healthcare institutions based on evidence-based medicine and cost-effectiveness. This policy initiative reflects the direction of "integration of East and West, complementary advantages," providing robust policy support for the collaboration between GUSHENGTANG and 1doc.
1doc is a subsidiary of IHG (IAPPS Health Group), a leading enterprise in Singapore’s healthcare sector, operating 9 owned clinics and 21 affiliated clinics. Using the 1doc Clinic Information System (CIS) and technologies such as digital twins, the company promotes the personalized, predictive, and preventive "3P Medicine" model. Currently, 1doc has served over 79,000 patients, supported more than 300 corporate clients, and provided workplace health services to over 25,000 employees, strengthening the local medical network and digital technology that empowers TCM deployment in Singapore.
As the first listed Chinese TCM chain service provider, GUSHENGTANG operates over 80 offline medical institutions in China and Singapore, serving over 20 million customers. Over its 15 years of establishment, GUSHENGTANG has accumulated a vast amount of high-quality clinical data, with over 18 million medical records and more than 40 million clinical prescriptions, creating a solid evidence-based foundation for verifying the clinical effectiveness of TCM, ensuring patient safety, and assessing cost-effectiveness.
This collaboration, leveraging a controlling operation model, aims to create a "New TCM" service model in Singapore, representing GUSHENGTANG's significant exploration of integrating digitization into international mainstream healthcare systems. In the future, both parties will explore more single-store partnership models, constructing a new collaborative treatment ecology of "co-creation, co-governance, and shared resources," facilitating the standardized and scalable development of TCM in the international market. Singapore's innovative policies and market openness in the realm of TCM and Western medicine integration provide GUSHENGTANG with a high-standard international testing ground. The technological solutions, compliance experiences, and operational models formed through this collaboration are expected to be replicated in Southeast Asia and even globally, aiding TCM in obtaining broader international recognition within the framework of evidence-based medicine.